{"release":{"schemaVersion":"maha-epistemic-release/1.0","releaseId":"epirelease_d92de3b10ecb4b8b82323b6b1d2e869e","releaseKind":"initial","status":"active","recordId":"urn:maha:record:ex-vivo-genome-editing-workflow","domainSlug":"synthetic-biology","targetSha256":"sha256:3e76f32cc4d0ff6e901f3aeecd576f89bfa43edf09be22e618256a3a0fcc9120","canonicalPath":"/knowledge/synthetic-biology/methods/ex-vivo-genome-editing-workflow","canonicalVersion":"1.0.0","supersedesReleaseId":null,"approvals":[{"scope":"boundary-adequacy","reviewId":"epireview_d9d3eb8c4ad24097a686ddc6c705944c","reviewSha256":"sha256:570aa31e58548742feace302924e5c1c96159dbb0da2578189afe61dde09d562","reviewedAt":"2026-08-30T16:02:01.225Z","reviewerKind":"internal-editorial","reviewMethod":"Each criterion is recomputed from the exact record, its inspected alignment audit, source identity, exact locator, rights basis, claim scope, boundary, uncertainty, replication status, prohibited inferences, and revision digest."},{"scope":"domain-fidelity","reviewId":"epireview_6707ebbe804a4c9da88ac3561c66bba1","reviewSha256":"sha256:2fe301d758508881060374cf4ce14a760a6391659c209b1106f111ee8ff35095","reviewedAt":"2026-08-30T16:02:01.157Z","reviewerKind":"internal-editorial","reviewMethod":"Each criterion is recomputed from the exact record, its inspected alignment audit, source identity, exact locator, rights basis, claim scope, boundary, uncertainty, replication status, prohibited inferences, and revision digest."},{"scope":"rights-and-locator","reviewId":"epireview_f6dde2cf887c49ff9075f97a6d5a08d9","reviewSha256":"sha256:daa85855db5ae97f025f30af9294dcfaf381927c34445add2a4ca1f9b647df91","reviewedAt":"2026-08-30T16:02:01.286Z","reviewerKind":"internal-editorial","reviewMethod":"Each criterion is recomputed from the exact record, its inspected alignment audit, source identity, exact locator, rights basis, claim scope, boundary, uncertainty, replication status, prohibited inferences, and revision digest."},{"scope":"source-fidelity","reviewId":"epireview_6aa0615fc7604a609635eda707393ac9","reviewSha256":"sha256:4648f48e40fa7314373be919e9cb34b2370b2bb9c58ba79462821261ee61b036","reviewedAt":"2026-08-30T16:02:01.089Z","reviewerKind":"internal-editorial","reviewMethod":"Each criterion is recomputed from the exact record, its inspected alignment audit, source identity, exact locator, rights basis, claim scope, boundary, uncertainty, replication status, prohibited inferences, and revision digest."}],"assuranceTier":"internally-reviewed-canonical","releaseAuthority":{"authoritySha256":"sha256:2a0161a3927ae8366af44bda6671b5249802843ff3895dc292c90e5466b88609","attribution":"withheld-by-consent"},"publicChangeSummary":"Initial canonical publication under the disclosed exact-revision internal editorial tier.","recordSha256":"sha256:835c473a58c8114c35a25c88d3e618e1f2954e0555c8c29bd0d89db232111877","gateDecision":{"reasons":[],"recordId":"urn:maha:record:ex-vivo-genome-editing-workflow","publicEligible":true,"evaluatedAgainst":"maha-epistemic/1.0"},"releasedAt":"2026-08-30T16:02:46.045Z","releaseSha256":"sha256:70b994e1d9c25bc2a5176c61c3d1caf77733c1bc72637204d58f2700a2497bf4","withdrawal":null},"provenance":{"schemaVersion":"maha-epistemic/1.0","evidencePolicyVersion":"mps/0.1","recordId":"urn:maha:record:ex-vivo-genome-editing-workflow","canonicalPath":"/knowledge/synthetic-biology/methods/ex-vivo-genome-editing-workflow","contentHash":"sha256:835c473a58c8114c35a25c88d3e618e1f2954e0555c8c29bd0d89db232111877","generatedAt":"2026-08-30T16:02:46.045Z","publicationDecision":{"recordId":"urn:maha:record:ex-vivo-genome-editing-workflow","publicEligible":true,"evaluatedAgainst":"maha-epistemic/1.0","reasons":[]},"claims":[{"id":"urn:maha:claim:ex-vivo-genome-editing-workflow","scope":"The constructs, biological systems, protocols, assays, datasets, and comparisons reported in CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.","boundary":"The workflow’s risks and outcomes are indication-, cell-product-, conditioning-, manufacturing-, participant-, and follow-up-specific.","claimKind":"empirical-claim","sourceIds":["source-frangoul-crispr-2021"],"statement":"The cited report describes collection, ex-vivo CRISPR-Cas9 editing, conditioning, transplantation, and early follow-up for two participants.","replication":{"asOfDate":"2026-08-24","assessment":"This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded.","independentReplicationCount":null},"uncertainty":{"kind":"qualitative","statement":"There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices."},"evidenceMaturity":"single-study"}],"sources":[{"id":"source-frangoul-crispr-2021","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2031054","title":"CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia","rights":{"note":"Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced.","basis":"citation-with-paraphrase","quotationUsed":false},"authors":["Haydar Frangoul","David Altshuler","M. Domenica Cappellini","Yi-Shan Chen","et al."],"boundary":"Two early cases do not establish population-level safety, durability, comparative effectiveness, or general readiness of genome editing.","publisher":"The New England Journal of Medicine","establishes":"The report describes ex-vivo CRISPR-Cas9 editing, conditioning, transplantation, and early clinical outcomes for two participants under a specific investigational protocol.","identifiers":[{"value":"10.1056/NEJMoa2031054","scheme":"doi"}],"publishedAt":"2020-12-05","exactLocator":"Abstract; Methods; Results; figures and tables for the two reported participants; supplementary protocol.","conflictsOfInterest":"The study was sponsored by CRISPR Therapeutics and Vertex Pharmaceuticals; author relationships are disclosed in the article."}],"reviewEvents":[{"reviewId":"epireview_6aa0615fc7604a609635eda707393ac9","scope":"source-fidelity","targetSha256":"sha256:3e76f32cc4d0ff6e901f3aeecd576f89bfa43edf09be22e618256a3a0fcc9120","reviewedAt":"2026-08-30T16:02:01.089Z","verdict":"approve","supersedesReviewId":null},{"reviewId":"epireview_6707ebbe804a4c9da88ac3561c66bba1","scope":"domain-fidelity","targetSha256":"sha256:3e76f32cc4d0ff6e901f3aeecd576f89bfa43edf09be22e618256a3a0fcc9120","reviewedAt":"2026-08-30T16:02:01.157Z","verdict":"approve","supersedesReviewId":null},{"reviewId":"epireview_d9d3eb8c4ad24097a686ddc6c705944c","scope":"boundary-adequacy","targetSha256":"sha256:3e76f32cc4d0ff6e901f3aeecd576f89bfa43edf09be22e618256a3a0fcc9120","reviewedAt":"2026-08-30T16:02:01.225Z","verdict":"approve","supersedesReviewId":null},{"reviewId":"epireview_f6dde2cf887c49ff9075f97a6d5a08d9","scope":"rights-and-locator","targetSha256":"sha256:3e76f32cc4d0ff6e901f3aeecd576f89bfa43edf09be22e618256a3a0fcc9120","reviewedAt":"2026-08-30T16:02:01.286Z","verdict":"approve","supersedesReviewId":null}]},"privacyBoundary":"Operational actor fingerprints, bearer credentials, private reviewer profiles, affiliations, conflicts, and non-consented authority identity fields are excluded."}